Key Highlights: Implications: Emcure’s move to take Gennova to 100% ownership and fold it under the “One Emcure” framework tightens control over a strategically important biologi...
Key Highlights: Implications: The slump sale of Gennova’s small mRNA unit to Immunoscript for ₹139.5 crore effectively exits Emcure from a non-core, low-contribution bu...
Key Highlights: Implications: Sun Pharma is making its biggest strategic pivot yet with the planned all‑cash takeover of Organon, using the deal to jump from an India‑anchor...
Latest Developments in the Biosimilar Market The global pharmaceutical industry is witnessing rapid growth in the biosimilars market as patents for several blockbuster biologic drugs begin to ex...
Latest Developments on GLP-1 Therapies In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as one of the fastest-growing segments in the global pharmaceutical market....
Key Highlights: Implications: Biocon is consolidating leadership under Shreehas Tambe to drive its newly integrated biosimilars–generics platform, with a clear focus on...
Key Highlights: Implications: The expanded BAT2506 deal gives Intas a late‑stage TNF‑α biosimilar in a broad immunology class, reinforcing its biologics presence in rheumatology ...
